Rainier Acquisition Corp.

Rainier Acquisition Corp.

RNAQ
Rainier Acquisition Corp.US flagNASDAQ
10.05
USD
+0.02
- -
86.68MMarket Cap
2024 Y
2025 Y
Revenue per Share
- -
- -
Basic EPS, GAAP
- -
- -
Free Cash Flow per Basic Share
- -
- -
Dividend per Share
- -
- -
Book Value per Share
- -
- -
Tangible Book Value per Share
- -
- -
Basic Weighted Avg Shares
8
8
Sales/Revenue/Turnover
- -
- -
Operating Margin (%)
- -
- -
Depreciation Expense
- -
- -
Net Income, GAAP
- -
- -
Effective Tax Rate (%)
- -
- -
Profit Margin (%)
- -
- -
Working Capital
- -
- -
LT Debt
- -
- -
Total Equity
- -
- -
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-100.29%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
63.71%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Gbola Amusa
Sector
Financial Services
Industry
Shell Companies
Address
1 Pennsylvania Plaza, Suite 4800 New York NY United States of America 10119
IPO Date
Sep 15, 2026
Website
sec.gov
Business
Rainier Acquisition Corporation is a Cayman Islands-domiciled special purpose acquisition company focused on identifying and partnering with category-defining life sciences companies to create long-term public-market value through scientific rigor, global sourcing and disciplined execution. Founded in 2023 and headquartered in New York, New York, the company operates through a unit structure that combines one Class A ordinary share and one-fourth of one redeemable warrant; its warrants are exercisable at $11.50 per share, and its securities trade on Nasdaq under the symbols RNAQU, RNAQ and RNAQW. The company’s strategy targets life sciences businesses across therapeutics, diagnostics, genomics, precision medicine, life-science tools and related healthcare technologies, with a focus on public and private market opportunities in the United States and other global markets. Recent company developments include the full exercise of the underwriter’s over-allotment option in its initial public offering, increasing total gross proceeds to $86.25 million, and the announced separation of its IPO units so that Class A ordinary shares and warrants can trade separately beginning September 15, 2026. The company is led by a management team and board with extensive experience in healthcare investing, capital markets, SPAC formation and biotechnology transactions, and it maintains its principal executive offices at 1 Penn Plaza, 48th Floor, New York, NY 10119.